UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Annals of oncology, 2020-06, Vol.31 (6), p.674-696

2020

Volltextzugriff (PDF)

Breast carcinoma—rare types: review of the literature

Annals of oncology, 2009-11, Vol.20 (11), p.1763-1770

2009

Volltextzugriff (PDF)

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome

Annals of oncology, 2012-02, Vol.23 (2), p.338-345

2012

Volltextzugriff (PDF)

Research needs in breast cancer

Annals of oncology, 2017-02, Vol.28 (2), p.208-217

2017

Volltextzugriff (PDF)

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?

Annals of oncology, 2012-04, Vol.23 (4), p.876-881

2012

Volltextzugriff (PDF)

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer

European journal of cancer (1990), 2013-07, Vol.49 (11), p.2469-2475

2013

Volltextzugriff (PDF)

Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1

Oncogene, 2010-12, Vol.29 (48), p.6343-6356

2010

Volltextzugriff (PDF)

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Annals of oncology, 2007-01, Vol.18 (1), p.45-51

2007

Volltextzugriff (PDF)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast cancer research and treatment, 2019-04, Vol.174 (3), p.719-729

2019

Volltextzugriff (PDF)

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Annals of oncology, 2022-11, Vol.33 (11), p.1097-1118

2022

Volltextzugriff (PDF)

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?

JNCI : Journal of the National Cancer Institute, 1999-08, Vol.91 (15), p.1281-1287

1999

Volltextzugriff (PDF)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of oncology, 2018-04, Vol.29 (4), p.888-894

2018

Volltextzugriff (PDF)

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Annals of oncology, 2016-06, Vol.27 (6), p.1013-1019

2016

Volltextzugriff (PDF)

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Investigational new drugs, 2013-12, Vol.31 (6), p.1522-1529

2013

Volltextzugriff (PDF)

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.143-151

2013

Volltextzugriff (PDF)

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Annals of oncology, 2018-03, Vol.29 (3), p.669-680

2018

Volltextzugriff (PDF)

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213

Breast cancer research and treatment, 2018, Vol.167 (2), p.485-493

2018

Volltextzugriff (PDF)

Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT

International journal of cardiology, 2017-10, Vol.245, p.263-270

2017

Volltextzugriff (PDF)

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.478-484

1999

Volltextzugriff (PDF)

Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer

Cancer nursing, 2007-03, Vol.30 (2), p.95-100

2007

Volltextzugriff (PDF)

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Annals of oncology, 2017-07, Vol.28 (7), p.1560-1568

2017

Volltextzugriff (PDF)

Phase I Study of Liposomal Vincristine

Journal of clinical oncology, 1999-02, Vol.17 (2), p.697-705

1999

Volltextzugriff (PDF)

LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation

Annals of oncology, 2018-10, Vol.29, p.viii120-viii120

2018

Volltextzugriff (PDF)

Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art

Current oncology (Toronto), 2012-10, Vol.19 (5), p.259-268

2012

Volltextzugriff (PDF)

Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2

Annals of oncology, 2018-10, Vol.29, p.viii107-viii108

2018

Volltextzugriff (PDF)

1 – 25 von 384

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(378)
Mit Volltextzugriff
(358)

Publikationsform

Sprache

Englisch
(384)

Erscheinungsjahr

n.n

Thema

Science & Technology
(176)
Life Sciences & Biomedicine
(171)
Humans
(162)
Oncology
(133)
Female
(130)
Biological And Medical Sciences
(81)
Middle Aged
(80)
Medical Sciences
(77)
Adult
(67)
Breast Neoplasms - Drug Therapy
(64)
Aged
(60)
Breast Cancer
(60)
Breast Neoplasms - Pathology
(52)
Antineoplastic Agents
(51)
Pharmacology. Drug Treatments
(50)
Chemotherapy
(49)
Tumors
(49)
Male
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(32)
Treatment Outcome
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Breast carcinoma—rare types: review of the literature

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome

Research needs in breast cancer

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer

Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment:Challenges for Drug Development?

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213

Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Phase I Study of Liposomal Vincristine

LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation

Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art

Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2

Suchergebnisse filtern